chenodeoxycholic acid has been researched along with Fatty Liver in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Gai, Z; Krajnc, E; Kullak-Ublick, GA; Samodelov, SL; Visentin, M | 1 |
| Adorini, L; Castelloe, E; Clopton, P; Dillon, P; Henry, RR; Kipnes, M; Marschall, HU; Morrow, L; Mudaliar, S; Pruzanski, M; Sanyal, AJ; Sciacca, CI; Shapiro, D | 1 |
| Karpen, SJ | 1 |
| Hayashi, Y; Ishii, A; Jia, X; Kaneko, R; Kato, M; Kitamori, K; Naito, H; Nakajima, T; Nomura, M; Suzuki, Y; Yamori, Y; Yetti, H; Zaitsu, K | 1 |
| Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Galli, A; Maggi, M; Maneschi, E; Mannucci, E; Morelli, A; Rastrelli, G; Saad, F; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Acco, A; Bastos-Pereira, AL; Chicorski, R; de Oliveira, LG; de Souza, CE; Dreifuss, AA; Fabossi, IA; Gremski, LH; Henneberg, R; Lívero, FA; Oude Elferink, RP; Rabitto, IS; Stolf, AM; Telles, JE | 1 |
| Jun, DW; Nguyen, MH; Oh, H; Saeed, WK | 1 |
| Barn, V; Farrell, GC; Geoffrey Haigh, W; Haczeyni, F; Ioannou, GN; Leclercq, IA; Mridha, AR; Poekes, L; Teoh, NC; Wang, H; Yeh, MM | 1 |
| Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
| Adorini, L; Pruzanski, M; Shapiro, D | 1 |
| Aranha, MM; Camilo, ME; Cortez-Pinto, H; Costa, A; da Silva, IB; de Moura, MC; Rodrigues, CM | 1 |
| Brunner, H; Grabner, G; Horak, W | 1 |
| Bochet, S; Borel, GA | 1 |
| Leuschner, U | 1 |
| Banwell, JG; Lockwood, DH; Nair, PP; Sherr, HP; White, JJ | 1 |
| Bergman, F; van der Linden, W | 1 |
2 review(s) available for chenodeoxycholic acid and Fatty Liver
| Article | Year |
|---|---|
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Topics: Biomarkers; Chenodeoxycholic Acid; Clinical Trials as Topic; Fatty Liver; Fibrosis; Humans; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Vitamin E | 2016 |
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Topics: Animals; Chenodeoxycholic Acid; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2012 |
1 trial(s) available for chenodeoxycholic acid and Fatty Liver
| Article | Year |
|---|---|
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Topics: Adult; Aged; Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2013 |
13 other study(ies) available for chenodeoxycholic acid and Fatty Liver
| Article | Year |
|---|---|
Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Topics: Animals; Antioxidants; Body Weight; Cell Line, Tumor; Chenodeoxycholic Acid; Cytochrome P-450 Enzyme System; Fatty Liver; Female; Lipid Metabolism; Liver; Liver Function Tests; Mice, Inbred C57BL; Oxidative Stress; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcriptome; Valproic Acid | 2020 |
Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?
Topics: Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2013 |
A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model.
Topics: Animals; Biomarkers; Chenodeoxycholic Acid; Cholic Acid; Chromatography, Liquid; Deoxycholic Acid; Diet, High-Fat; Fatty Liver; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Random Allocation; Rats; Tandem Mass Spectrometry | 2014 |
Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Chenodeoxycholic Acid; Diet, High-Fat; Dietary Fats; Erectile Dysfunction; Fatty Liver; Gene Expression; Humans; Imidazoles; Infliximab; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Rabbits; Receptors, Cytoplasmic and Nuclear; Sulfones; Testosterone; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride | 2014 |
The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Catalase; Chenodeoxycholic Acid; Cholesterol; Ethanol; Fatty Liver; Gastrointestinal Agents; Glutathione Transferase; Histocytochemistry; Liver Diseases, Alcoholic; Male; Mice; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Superoxide Dismutase; Triglycerides | 2014 |
Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.
Topics: Adiposity; Animals; Chenodeoxycholic Acid; Diet, Atherogenic; Disease Models, Animal; Fatty Liver; Female; Inflammation; Liver; Mice; Mice, Inbred NOD; Mice, Obese; Obesity; Weight Gain | 2017 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Bile acid levels are increased in the liver of patients with steatohepatitis.
Topics: Adult; Bile Acids and Salts; Biopsy; Chenodeoxycholic Acid; Cholic Acid; Chromatography, Gas; Deoxycholic Acid; Disease Progression; Fatty Liver; Fatty Liver, Alcoholic; Female; Humans; Liver; Male; Middle Aged; Severity of Illness Index | 2008 |
[Adverse effects of chenodeoxycholic-acid therapy].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; Cholelithiasis; Cholestasis; Fatty Liver; Humans | 1976 |
[Clinical application of the radiolabeled bile salt tolerance test].
Topics: Chenodeoxycholic Acid; Fatty Liver; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Radionuclide Imaging | 1978 |
[Dissolution of cholesterol calculi using chenodeoxycholic acid].
Topics: Alcoholism; Chenodeoxycholic Acid; Cholecystitis; Cholelithiasis; Cholestasis; Cholesterol; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis | 1976 |
Bile acid metabolism and hepatic disease following small bowel bypass for obesity.
Topics: Adult; Bile; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholic Acids; Deoxycholic Acid; Fatty Liver; Female; Glycine; Humans; Ileum; Jejunum; Lithocholic Acid; Liver; Liver Cirrhosis; Liver Diseases; Male; Obesity; Postoperative Complications; Protein Deficiency; Sulfuric Acids; Taurine | 1974 |
Liver morphology and gallstone formation in hamsters and mice treated with chenodeoxycholic acid.
Topics: Animals; Bile; Bile Acids and Salts; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Cholesterol, Dietary; Cricetinae; Diet; Fatty Liver; Female; Liver; Male; Mice | 1973 |